Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $20.33

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $20.3333.

Several equities analysts have issued reports on ENTA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Wednesday, January 21st. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 10th. Finally, JPMorgan Chase & Co. assumed coverage on Enanta Pharmaceuticals in a research note on Friday, November 14th. They set an “overweight” rating and a $17.00 target price for the company.

Enanta Pharmaceuticals Price Performance

NASDAQ:ENTA opened at $13.89 on Thursday. Enanta Pharmaceuticals has a 12 month low of $4.09 and a 12 month high of $17.15. The firm has a market capitalization of $403.09 million, a PE ratio of -4.34 and a beta of 0.98. The business’s fifty day moving average price is $14.06 and its 200 day moving average price is $11.62.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.12. The business had revenue of $18.62 million during the quarter, compared to analysts’ expectations of $16.14 million. Enanta Pharmaceuticals had a negative return on equity of 78.58% and a negative net margin of 106.80%. As a group, equities analysts anticipate that Enanta Pharmaceuticals will post -4.65 EPS for the current year.

Insider Buying and Selling

In related news, insider Yat Sun Or sold 2,390 shares of Enanta Pharmaceuticals stock in a transaction on Friday, December 5th. The stock was sold at an average price of $14.23, for a total transaction of $34,009.70. Following the completion of the transaction, the insider directly owned 371,392 shares of the company’s stock, valued at approximately $5,284,908.16. The trade was a 0.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Tara Lynn Kieffer sold 2,106 shares of Enanta Pharmaceuticals stock in a transaction on Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $29,968.38. Following the transaction, the insider directly owned 30,620 shares of the company’s stock, valued at $435,722.60. This trade represents a 6.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 11,961 shares of company stock worth $170,149 in the last quarter. Company insiders own 11.48% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ENTA. CWM LLC increased its stake in Enanta Pharmaceuticals by 22.1% in the second quarter. CWM LLC now owns 21,464 shares of the biotechnology company’s stock valued at $162,000 after purchasing an additional 3,879 shares during the last quarter. Bank of Montreal Can raised its holdings in Enanta Pharmaceuticals by 32.8% in the second quarter. Bank of Montreal Can now owns 33,868 shares of the biotechnology company’s stock valued at $256,000 after buying an additional 8,365 shares during the period. Tudor Investment Corp ET AL acquired a new position in shares of Enanta Pharmaceuticals during the 3rd quarter valued at $125,000. Harvest Investment Services LLC acquired a new position in shares of Enanta Pharmaceuticals during the third quarter worth about $146,000. Finally, Quarry LP acquired a new position in Enanta Pharmaceuticals during the 3rd quarter worth approximately $81,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct?acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.